Neulasta Onpro: a coup de grâce?
- PMID: 36947018
- DOI: 10.37765/ajmc.2023.89331
Neulasta Onpro: a coup de grâce?
Abstract
With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources